A potential improvement of rheumatoid arthritis in a patient treated with liraglutide for glucocorticoid-induced diabetes

Michiko Kohno, Masatoshi Nomura, Ichiro Abe, Yusuke Matsumura, Yayoi Matsuda, Masahiro Adachi, Hisaya Kawate, Keizo Ohnaka, Takahiko Horiuchi, Ryoichi Takayanagi

Research output: Contribution to journalArticle

Abstract

A 74-year-old male, who had been prescribed prednisolone (PSL) for rheumatoid arthritis (RA) since age 63 and who had developed glucocorticoid-induced diabetes at age 69, was hospitalized due to poor glycemic control. On admission, he was taking 7.5 mg/day of PSL and his Hb Ale was 8.1 % despite infusion of 27 U/day of insulin. As preserved β-cell function was confirmed by a glucagon challenge test, liraglutide therapy was introduced. A stepwise increase in liraglutide successfully improved his glucose tolerance and led to discontinuation of insulin treatment A good glycemic control was finally achieved by the combination of 0.9 mg/day of liraglutide and 3 mg/day of glimepiride. Interestingly, the level of matrix metalloproteinase-3, which indicates the RA activity, was dramatically reduced from 356 ng/m/to 187 ng/m/in parallel with this treatment. The present case may imply that there is a correlation between the administration of glucagon-like peptide-1 and an improvement in the symptoms associated with rheumatoid arthritis.

Original languageEnglish
Pages (from-to)179-184
Number of pages6
JournalJournal of the Japan Diabetes Society
Volume56
Issue number3
Publication statusPublished - Mar 1 2013

Fingerprint

Glucocorticoids
Rheumatoid Arthritis
glimepiride
Prednisolone
Insulin
Matrix Metalloproteinase 3
Glucagon-Like Peptide 1
Glucagon
Therapeutics
Glucose
Liraglutide

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

A potential improvement of rheumatoid arthritis in a patient treated with liraglutide for glucocorticoid-induced diabetes. / Kohno, Michiko; Nomura, Masatoshi; Abe, Ichiro; Matsumura, Yusuke; Matsuda, Yayoi; Adachi, Masahiro; Kawate, Hisaya; Ohnaka, Keizo; Horiuchi, Takahiko; Takayanagi, Ryoichi.

In: Journal of the Japan Diabetes Society, Vol. 56, No. 3, 01.03.2013, p. 179-184.

Research output: Contribution to journalArticle

Kohno, Michiko ; Nomura, Masatoshi ; Abe, Ichiro ; Matsumura, Yusuke ; Matsuda, Yayoi ; Adachi, Masahiro ; Kawate, Hisaya ; Ohnaka, Keizo ; Horiuchi, Takahiko ; Takayanagi, Ryoichi. / A potential improvement of rheumatoid arthritis in a patient treated with liraglutide for glucocorticoid-induced diabetes. In: Journal of the Japan Diabetes Society. 2013 ; Vol. 56, No. 3. pp. 179-184.
@article{81f59dac59fb4609a739be32cb5ae4b9,
title = "A potential improvement of rheumatoid arthritis in a patient treated with liraglutide for glucocorticoid-induced diabetes",
abstract = "A 74-year-old male, who had been prescribed prednisolone (PSL) for rheumatoid arthritis (RA) since age 63 and who had developed glucocorticoid-induced diabetes at age 69, was hospitalized due to poor glycemic control. On admission, he was taking 7.5 mg/day of PSL and his Hb Ale was 8.1 {\%} despite infusion of 27 U/day of insulin. As preserved β-cell function was confirmed by a glucagon challenge test, liraglutide therapy was introduced. A stepwise increase in liraglutide successfully improved his glucose tolerance and led to discontinuation of insulin treatment A good glycemic control was finally achieved by the combination of 0.9 mg/day of liraglutide and 3 mg/day of glimepiride. Interestingly, the level of matrix metalloproteinase-3, which indicates the RA activity, was dramatically reduced from 356 ng/m/to 187 ng/m/in parallel with this treatment. The present case may imply that there is a correlation between the administration of glucagon-like peptide-1 and an improvement in the symptoms associated with rheumatoid arthritis.",
author = "Michiko Kohno and Masatoshi Nomura and Ichiro Abe and Yusuke Matsumura and Yayoi Matsuda and Masahiro Adachi and Hisaya Kawate and Keizo Ohnaka and Takahiko Horiuchi and Ryoichi Takayanagi",
year = "2013",
month = "3",
day = "1",
language = "English",
volume = "56",
pages = "179--184",
journal = "Journal of the Japan Diabetes Society",
issn = "0021-437X",
publisher = "Japan Diabetes Society",
number = "3",

}

TY - JOUR

T1 - A potential improvement of rheumatoid arthritis in a patient treated with liraglutide for glucocorticoid-induced diabetes

AU - Kohno, Michiko

AU - Nomura, Masatoshi

AU - Abe, Ichiro

AU - Matsumura, Yusuke

AU - Matsuda, Yayoi

AU - Adachi, Masahiro

AU - Kawate, Hisaya

AU - Ohnaka, Keizo

AU - Horiuchi, Takahiko

AU - Takayanagi, Ryoichi

PY - 2013/3/1

Y1 - 2013/3/1

N2 - A 74-year-old male, who had been prescribed prednisolone (PSL) for rheumatoid arthritis (RA) since age 63 and who had developed glucocorticoid-induced diabetes at age 69, was hospitalized due to poor glycemic control. On admission, he was taking 7.5 mg/day of PSL and his Hb Ale was 8.1 % despite infusion of 27 U/day of insulin. As preserved β-cell function was confirmed by a glucagon challenge test, liraglutide therapy was introduced. A stepwise increase in liraglutide successfully improved his glucose tolerance and led to discontinuation of insulin treatment A good glycemic control was finally achieved by the combination of 0.9 mg/day of liraglutide and 3 mg/day of glimepiride. Interestingly, the level of matrix metalloproteinase-3, which indicates the RA activity, was dramatically reduced from 356 ng/m/to 187 ng/m/in parallel with this treatment. The present case may imply that there is a correlation between the administration of glucagon-like peptide-1 and an improvement in the symptoms associated with rheumatoid arthritis.

AB - A 74-year-old male, who had been prescribed prednisolone (PSL) for rheumatoid arthritis (RA) since age 63 and who had developed glucocorticoid-induced diabetes at age 69, was hospitalized due to poor glycemic control. On admission, he was taking 7.5 mg/day of PSL and his Hb Ale was 8.1 % despite infusion of 27 U/day of insulin. As preserved β-cell function was confirmed by a glucagon challenge test, liraglutide therapy was introduced. A stepwise increase in liraglutide successfully improved his glucose tolerance and led to discontinuation of insulin treatment A good glycemic control was finally achieved by the combination of 0.9 mg/day of liraglutide and 3 mg/day of glimepiride. Interestingly, the level of matrix metalloproteinase-3, which indicates the RA activity, was dramatically reduced from 356 ng/m/to 187 ng/m/in parallel with this treatment. The present case may imply that there is a correlation between the administration of glucagon-like peptide-1 and an improvement in the symptoms associated with rheumatoid arthritis.

UR - http://www.scopus.com/inward/record.url?scp=84876499777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876499777&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84876499777

VL - 56

SP - 179

EP - 184

JO - Journal of the Japan Diabetes Society

JF - Journal of the Japan Diabetes Society

SN - 0021-437X

IS - 3

ER -